AAX Biotech, founded by experts from Karolinska Institutet in Stockholm, Sweden, and Daiichi Sankyo are collaborating in the evaluation of AAX Biotech’s Opti-mAb®technology.
AAX Biotech pioneers innovative technologies that advance the development of next-generation antibody therapeutics. Its two platforms, Seqitope® and Opti-mAb®, address key challenges in antibody engineering and therapeutic design. The technologies enable high throughput and high-resolution epitope mapping as well as stabilization of single chain variable fragments (scFv) for applications such as bispecific antibodies and CAR-T cells. Both technologies aim to produce better and more effective antibody-based medicines.
Daiichi Sankyo through its Daiichi Sankyo Research Institute in Munich will evaluate the capabilities of Opti-mAb® and explore opportunities for broader collaboration aimed at addressing critical unmet medical needs. AAX Biotech’s unique Opti-mAb® platform stabilizes the inherently unstable single-chain variable fragment (scFv) antibodies .
“For AAX Biotech, collaborating with a company with the scale and reputation of Daiichi Sankyo represents a tremendous validation of our innovative approach,” says Maria Lisa Knudsen, CEO of AAX Biotech.
“This provides us with the opportunity to showcase the power of Opti-mAb® in collaboration with a truly global leader in pharmaceutical innovation. We are excited to work closely with the world-class scientific teams at Daiichi Sankyo.”
This collaboration highlights AAX Biotech commitment to exploring cutting-edge science to advance precision medicine and improve patient outcomes worldwide.
Featured image Courtesy: © 2010 – 2025 Fotolia/Adobe. Used with permission.
DOI
